TY - JOUR
T1 - Exploring passive immunization therapies for COVID-19 management in rheumatic patients
AU - Kow, Chia Siang
AU - Ramachandram, Dinesh Sangarran
AU - Hasan, Syed Shahzad
AU - Thiruchelvam, Kaeshaelya
PY - 2024/9
Y1 - 2024/9
N2 - We extend our appreciation to Çimen Güneş et al. for their insightful retrospective study shedding light on the impact of coronavirus disease 2019 (COVID-19) on patients with rheumatic diseases. Their thorough retrospective assessment of over 10 000 patients provides invaluable insights into the frequency and mortality rates associated with COVID-19 in this vulnerable population. The study's findings unveil critical insights that demand thoughtful consideration in clinical practice. Firstly, the incidence of COVID-19 among patients with rheumatic diseases is significant, with more than a quarter of individuals testing positive for the virus during the study period. This underscores the heightened vulnerability of this patient cohort to SARS-CoV-2 infection, likely attributed to underlying immune dysregulation linked to their rheumatic conditions and the immunosuppressive therapies they receive.
AB - We extend our appreciation to Çimen Güneş et al. for their insightful retrospective study shedding light on the impact of coronavirus disease 2019 (COVID-19) on patients with rheumatic diseases. Their thorough retrospective assessment of over 10 000 patients provides invaluable insights into the frequency and mortality rates associated with COVID-19 in this vulnerable population. The study's findings unveil critical insights that demand thoughtful consideration in clinical practice. Firstly, the incidence of COVID-19 among patients with rheumatic diseases is significant, with more than a quarter of individuals testing positive for the virus during the study period. This underscores the heightened vulnerability of this patient cohort to SARS-CoV-2 infection, likely attributed to underlying immune dysregulation linked to their rheumatic conditions and the immunosuppressive therapies they receive.
UR - http://www.scopus.com/inward/record.url?scp=85202920204&partnerID=8YFLogxK
U2 - 10.1111/1756-185X.15325
DO - 10.1111/1756-185X.15325
M3 - Letter
C2 - 39221822
AN - SCOPUS:85202920204
SN - 1756-1841
VL - 27
JO - International Journal of Rheumatic Diseases
JF - International Journal of Rheumatic Diseases
IS - 9
M1 - e15325
ER -